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In the past decade, the fundamental importance and therapeutic potential of costimulatory signals for lymphocyte activation have spurred a large
amount of work in immunology, infection, cancer, autoimmune diseases, etc. However, the mechanisms behind T cell costimulation remain unclear,
partly due to the lack of suitable techniques. There is an urgent need for functional genomic research to develop comprehensive approaches to direct
identification of protein–protein interactions that are dependent on the posttranslational modification of one component of the complex, particularly
in the field of Tcell immunology. Using inducible costimulator (ICOS) as a model, we failed to find any proteins that associated with the cytoplasmic
tail of ICOS by the yeast two-hybrid approach. Therefore, we have developed a new yeast three-hybrid system that facilitates the rapid screening of
cDNA libraries to find signaling molecules that interact with phosphorylated T cell costimulatory receptors. We demonstrate the utility of this
technique to detect the interaction between ICOS and the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K). The p85 unit of PI3K is the
only signaling molecule identified so far that interacts with ICOS. This system may be of great help in dissecting the mechanisms of T cell
costimulation and could be applied to other receptors.
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engagement of the antigen receptor and that the response that
follows is regulated and shaped by other molecules collectively
known as costimulators. The prototypical costimulatory receptor
is CD28, which upon interaction with B7-1 or B7-2 provides
signals that are required for optimal activation. The CD28
homolog CTLA-4, which also binds B7-1 and B7-2, attenuates T
cell responses [1–3]. Recently additional molecules in the
extended CD28/B7 family that orchestrate the emerging T cell
response have been found [3–5]. These include inducible
costimulator (ICOS) and programmed death 1 (PD-1) [6], which
bind respectively B7h [7–11] and PD-L1/PD-L2 [12–15]. B7H3
[16] and B7x [17] (also known as B7H4 [18] and B7S1 [19]) are
the newest members of the B7 ligand family and their receptors⁎ Corresponding author. Fax: +1 646 422 0470.
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doi:10.1016/j.ygeno.2006.08.012are currently unknown. The precise roles of these new pathways
in regulating T cell responses are not well established, and their
signaling pathways are poorly understood. For example, while it
is clear that ICOS can regulate Th2 cytokine production and
plays a critical role in T/B cooperation, the mechanism of its
action is as yet unknown.
A central question in the study of T cell costimulatory recep-
tor-mediated signaling pathways is to determine what other
proteins interact with them.Many approaches have been taken to
identify protein–protein interactions. One approach is the yeast
two-hybrid system [20,21], which has been a very powerful tool
in identifying molecules that interact with the cytoplasmic
domains of cell surface receptors. However, we found that the
conventional two-hybrid system did not reveal any proteins that
associated with the cytoplasmic tail of ICOS. The two-hybrid
system does not allow detection of components that interact with
members of signaling pathways that require modification to
Fig. 1. Summary of yeast two-hybrid screen with ICOS and PD-1. The
cytoplasmic domain of mouse ICOS was used as bait to screen a cDNA library
from T cells, using the yeast two-hybrid system. It did not yield any molecules
specifically binding to the cytoplasmic tail of ICOS. Analogous to the ICOS
screen, the entire cytoplasmic region of PD-1 was used to screen the same mouse
T cell library, and two PD-1-specific positive clones were obtained.
842 X. Zang et al. / Genomics 88 (2006) 841–845associate. Amodified version of the two-hybrid systemwas used
to show that phosphorylated human killer cell receptors and
CD28 can bind signaling molecules [21–23]. Using ICOS as a
model, we describe a yeast three-hybrid system to identify a
molecule that interacts with the phosphorylated cytoplasmic tail
of ICOS. This system may be a valuable tool for screening
signaling molecules that interact with phosphorylated T cell
costimulatory receptors, as well as with other receptors.
Results
ICOS is a type I transmembrane protein with a 35- to 44-
amino-acid intracellular cytoplasmic domain that lacks intrinsic
catalytic functions, suggesting that intracellular signals are
mediated by other molecules that associate with ICOS. To
analyze the signal transduction of ICOS, we searched for
potential candidates that bind the cytoplasmic region of ICOS byFig. 2. The tyrosine residues of the ICOS cytoplasmic tail are conserved and could
tail of ICOS found in human (GenBank Accession No. CAC06612), mouse (Gen
bovine (GenBank Accession No. AAX46485), dog (GenBank Accession No. AAQ
acids are highlighted in boldface. The potential tyrosine phosphorylation site is in
TCR transgenic mice were activated with OVA323-339 peptide and treated with
(lanes 2 and 5) were immunoprecipitated with mAb to ICOS and then detect
phosphotyrosine (lanes 4, 5–6).first utilizing a standard yeast-two hybrid system. The entire
cytoplasmic region of mouse ICOS was used as bait. A mouse T
cell library constructed in the GAL4 activation domain plasmid
pACT was screened using this bait. Screening of approximately
5×106 cotransformed clones, surprisingly, did not yield any
ICOS-specific positive clones (Fig. 1). This was in contrast to
similar screens using unmodified CD28 and CTLA-4 cytoplas-
mic tails as baits, which yielded serine/threonine phosphatase
PP2A [24] and clathrin-coated pit adaptor protein AP50 [25–28].
Analogous to the ICOS screen, we used the entire cytoplasmic
region of PD-1 as a bait to screen the same mouse T cell library
and obtained two PD-1-specific positive clones by screening
only about 1.5×106 cotransformed clones (Fig. 1). These
results suggest that ICOS has a unique signaling pathway.
The ICOS gene has been cloned from human, mouse, rat,
dog, bovine, and chicken. Protein sequence alignment analysis
reveals that the cytoplasmic tail of ICOS is evolutionarily
conserved (Fig. 2A). In particular, the C-terminal tyrosine is
located within a highly conserved Tyr-Met-Phe-Met motif,
suggesting that some signaling molecules may bind only
tyrosine-phosphorylated ICOS. To determine whether the
tyrosine residue of the ICOS cytoplasmic tail is phosphory-
lated during T cell activation, cells from the lymph nodes and
spleens of DO11.10 TCR transgenic mice were activated with
OVA323-339 peptide for 60 h. Following a 10-min treatment
with the phosphatase inhibitor pervanadate, which increase the
level of tyrosine phosphorylation, ICOS was immunoprecipi-
tated to examine tyrosine phosphorylation using a mAb
against phosphotyrosine. As expected, activated, but not naïve,
T cells expressed ICOS. More importantly, at least some parts
of the ICOS protein from activated T cells were tyrosine
phosphorylated (Fig. 2B), suggesting that ICOS can be
induced to undergo tyrosine phosphorylation during T cell
activation.
To identify signaling molecules that bind phosphorylated
ICOS, a new yeast three-hybrid system was developed (Fig.
3A). Because yeast cells do not contain tyrosine kinases, we
cloned the mouse tyrosine kinase p56Lck into the NotI site
of the multiple cloning site II of ICOS/pBridge, thus creatingbe phosphorylated during T cell activation. (A) Comparison of the cytoplasmic
Bank Accession No. CAB71153), rat (GenBank Accession No. BAA82128),
20845), and chicken (GenBank Accession No. XP_421959). Identical amino
dicated with an arrow. (B) Cells from lymph nodes and spleens of DO11.10
pervanadate. The lysates of activated (lanes 3 and 6) and nonactivated cells
ed by Western blot with mAb against ICOS (lanes 1–3) or mAb against
Fig. 3. A genetic system for screening signaling proteins interacting with phosphorylated ICOS. (A) Scheme for the new screening system. A single vector expresses
two proteins, a bait and Lck, which is controlled by a conditional methionine promoter. Both are targeted into the nucleus, where Lck can phosphorylate the bait
protein. Phosphorylated bait binds a protein from the T cell library and initiates the expression of the reporter genes. (B) Yeast cells transformed with ICOS/pBridge
(lane 1) or ICOS/p56Lck/pBridge (lane 2) were grown on SD/−Trp/−Met medium. Phosphorylated proteins were detected by Western blot of total yeast protein
extracts and detection using a mAb against phosphotyrosine. (C) Yeast cells containing ICOS/p56Lck/pBridge were transformed with a mouse T cell library and
screening of approximately 1 million cotransformed clones yielded 5 positive clones.
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pBridge expresses two fusion proteins, one containing the
GAL4 DNA binding domain and the ICOS cytoplasmic tail, the
other containing a nuclear localization sequence and p56Lck.
The nuclear localization sequence ensures that p56Lck is in the
nucleus, where it can phosphorylate target proteins. The
expression of p56Lck is controlled by a conditional methionine
promoter, so that it is expressed in the absence of methionine.
This allows p56Lck expression to be switched on or off by a
simple replica plating step. The tyrosine kinase activity of
p56Lck in yeast was verified by Western blot (Fig. 3B).
Expression of plasmid ICOS/p56Lck/pBridge in yeast cells
enabled phosphorylation of yeast proteins, while no phospho-
tyrosine was detected in yeast containing ICOS/pBridge. The
same mouse T cell library was screened using this new system
and screening of approximately 1×106 cotransformed clones
yielded 108 clones selected by growth on SD/−Trp/−Leu/−His/
−Met plates; 7 were positive for β-galactosidase activity, and 5
were ICOS specific. All 5 positive clones encoded phosphati-
dylinositol 3-kinase (PI3K) p85 (Fig. 3C).
PI3K p85 protein contains one SH3 domain and two SH2
domains. To see if the whole PI3K p85 molecule or just oneFig. 4. PI3K p85 can be detected as a component of the ICOS signaling
complex. (A) Schematic diagram of five positive cDNA clones encoding PI3K
p85. (B) Cells from the lymph nodes and spleens of DO11.10 TCR transgenic
mice were activated with OVA323-339 peptide and treated with (lanes 3 and 4)
or without (lanes 1 and 2) pervanadate. The cellular lysates were immunopre-
cipitated with a mAb to ICOS (lanes 1 and 3) or control Ab (lanes 2 and 4) and
then Western blotted with a mAb against phosphotyrosine.domain is necessary for binding to ICOS, we sequenced all
inserts from the five positive clones. Protein sequence alignment
revealed that all five clones corresponded to the second SH2
domain of the p85 regulatory subunit of PI3K (Fig. 4A), sug-
gesting that PI3K p85 binds phosphorylated ICOS via the SH2
domain.
To determine whether PI3K p85 interacts with ICOS in vivo,
ICOS was immunoprecipitated from OVA323-339 peptide-
activated DO11.10 TCR transgenic T cell lysates and the pre-
sence of ICOS-associated endogenous PI3K p85 was exam-
ined by Western blot. As shown in Fig. 4B, PI3K p85 was
found to coimmunoprecipitate with ICOS. Thus, in vivo, PI3K
p85 can be detected as a component of the ICOS signaling
complex.
Discussion
Protein–protein interactions are intrinsic to virtually every
cellular process, including replication, transcription, secretion,
signal transduction, and metabolism, and alterations of protein–
protein interactions are known to contribute to many diseases.
Traditionally, the tools to detect interacting proteins include
techniques such as affinity chromatography, coimmunoprecipi-
tation, crosslinking, and glycerol gradient sedimentation [29].
These biochemical approaches are time-consuming and can be
difficult undertakings. The yeast two-hybrid system is a genetic
system that has provided enormous insights into the under-
standing of protein–protein interactions in various signal
pathways and has very recently been applied to the entire
protein complement of yeast [30], Caenorhabditis elegans [31],
and Drosophila melanogaster [32].
ICOS is a T cell costimulatory receptor with an intracellular
cytoplasmic domain that lacks intrinsic catalytic functions, sug-
gesting that intracellular signals are mediated by other molecules
that associate with ICOS. Therefore, a standard yeast two-hybrid
approach was first used to search for potential candidates that
844 X. Zang et al. / Genomics 88 (2006) 841–845bind the cytoplasmic region of ICOS. Despite an extensive
library screen, however, we failed to detect any molecules that
could bind the unmodified form of ICOS. There is an urgent
need to develop comprehensive approaches for direct identifi-
cation of protein–protein interactions that are dependent on the
posttranslational modification of one component of the complex.
ICOS contains an evolutionarily conserved tyrosine residue
in the cytoplasmic region and can be induced to undergo tyrosine
phosphorylation during T cell activation. The tyrosine kinases
responsible for ICOS tyrosine phosphorylation in activated T
cells have not yet been identified. We used p56Lck in our three-
hybrid screen system since it has been reported that Lck can
induce tyrosine phosphorylation of CD28 and CTLA-4 when
coexpressed in cell lines [33]. Using the new yeast three-hybrid
system, we rapidly identified that the p85 regulatory subunit of
PI3K bound tyrosine-phosphorylated ICOS. This result is in
agreement with other reports using biochemical approaches to
show that the phosphorylated cytoplasmic domain of an ICOS–
GST recombinant protein bound PI3K p85 [34] and that ICOS
and PI3K p85 coimmunoprecipitated after anti-CD3/ICOS
crosslinking [35]. We further demonstrated that the binding is
mediated through the second SH2 domain of the p85 unit. PI3K
is the only signaling molecule known to interact with ICOS so
far; the role of this pathway in ICOS-meditated Th2 cytokine
production and T/B cooperation remains to be explored.
Costimulatory molecules are essential for the communication
of T cells with virtually all other host cells. Because of the
fundamental biological importance and therapeutic potential of
T cell costimulatory receptors, there has been great interest in
identifying components of their signaling pathways. However,
the mechanisms behind Tcell costimulation mediated by CTLA-
4, ICOS, and PD-1 remain unclear. Despite considerable re-
search on CD28, the molecular mechanism by which CD28
crosslinking affects Tcell activation is incompletely understood.
In recent years, one of the emerging paradigms for T cell signal
transduction is that all known costimulatory receptors undergo
tyrosine phosphorylation upon interaction with the B7 ligand
family and that signaling molecules interact not in isolation but
through the recruitment of a complex of other proteins. To
facilitate the study of posttranslational modifications that
mediate interactions in T cell costimulatory signal transduction,
we have demonstrated here the use of a three-hybrid system for
rapid screening of cDNA libraries, to find signaling molecules
that interact with phosphorylated ICOS. This strategy could be
applied to the other recently discovered T cell costimulatory
molecules, as well as to other receptors.Materials and methods
Antibodies, cDNA library, peptide, and mice
Antibodies used in the study include monoclonal anti-ICOS (eBioscience),
anti-phosphotyrosine (Upstate Biotechnology), and polyclonal anti-p85 of PI3K
(Upstate Biotechnology). A mouse Tcell cDNA library constructed in the GAL4
activation domain plasmid pACT was previously described [25]. OVA323-339
peptide was synthesized at the Cancer Research Laboratory Microchemical
Facility of the University of California at Berkeley, by standard fluorenyl-
methoxycarbonyl synthesis. Peptides were purified by reverse-phase HPLC(>99%) and purity was verified by mass spectroscopy. DO11.10 TCR transgenic
mice were bred in-house.
Plasmid construction
The ICOS/pBridge and PD-1/pBridge plasmids were generated by
polymerase chain reaction (PCR) amplification of the cDNAs encoding the
murine ICOS cytoplasmic domain amino acids 166–200 and the PD-1
cytoplasmic domain amino acids 196–288, respectively, and subcloning into
the SalI site of the yeast expression vector pBridge (Clontech). The ICOS/
pBridge and PD-1/pBridge express a fusion protein containing the GAL4 DNA
binding domain and ICOS cytoplasmic tail or PD-1 cytoplasmic tail,
respectively. The open reading frame of murine p56Lck was PCR amplified
from a plasmid (a gift from Dr. Sue Sohn, University of California at Berkeley)
and inserted into theNotI site of pBridge and ICOS/pBridge to generate p56Lck/
pBridge and p56Lck/ICOS/pBridge, respectively. Both p56Lck/pBridge and
p56Lck/ICOS/pBridge express a hybrid p56Lck protein that is targeted to the
yeast nucleus by N-terminal nuclear localization sequences.
Yeast two-hybrid screen
The ICOS/pBridge or PD-1/pBridge construct was transfected into yeast
strain Y190 along with a mouse peripheral Tcell library constructed in the GAL4
activation domain plasmid pACT, and the two-hybrid screen was performed as
previously described [25]. A result was scored positive if both growth in the
absence of histidine occurred and β-galactosidase activity was observed.
Yeast three-hybrid system
Yeast strain Y190 transformed with ICOS/p56Lck/pBridge was grown on SD/
−Trp plates and then in SD/−Trp/−Met medium overnight. The ICOS/p56Lck/
pBridge/Y190 cells were transformed with a mouse Tcell library constructed in the
GAL4 activation domain plasmid pACT [25] according to the high-efficiency
transformation protocol [36] and grown on SD/−Trp/−Leu/−His/−Met plates
containing 5 mM 3-AT. A result was scored positive if both growth on an SD/−Trp/
−Leu/−His/−Met plate occurred and β-galactosidase activity was observed. The
plasmids were extracted from a single positive clone and transformed into Escher-
ichia coli XL1-Blue before sequencing. Yeast proteins were obtained with the
Y-PER yeast protein extraction reagent (Pierce) using the manufacturer's protocol.
T cell stimulation, immunoprecipitation, and Western blot
Cells from the lymph nodes and spleens of DO11.10 TCR transgenic mice
were activated with OVA323-339 peptide for 48–60 h and then lysed for 4 h in
the lysis buffer (1%NP-40, 300mMNaCl, 5 mMEDTA, 10 mM iodoacetamide,
protease inhibitor cocktail, 50 mMTris–HCl, pH 7.5). Cell lysates were clarified
by centrifugation and immunoprecipitated using protein G beads coated with
anti-ICOS antibody. After 6–8 h of incubation at 4°C, the immunoprecipitates
were washed using 1% NP-40 lysis buffer, and bound proteins were eluted by
boiling in SDS sample buffer, separated by SDS–polyacrylamide electropho-
resis, and transferred onto nitrocellulose membranes. Membranes were blocked
with 4% BSA in PBS and then incubated with anti-ICOS, anti-phosphotyrosine,
or anti-p85 of PI3K and subsequently with horseradish peroxidase-conjugated
secondary antibody before visualization using the ECL reagents (Amersham).
Pervanadate treatment
The pervanadate solution was made fresh as previously described [26]. H2O
(0.45 volume), 1 M H2O2 (0.5 volume), and Na3VO4 (0.05 volume) were mixed
and left for 15 min at room temperature. Cells were mixed with 1/50 volume of
the pervanadate solution and incubated for 10 min at 37°C.
Sequence analysis
Public databases were explored using BLAST searches with protein and
nucleotide sequences. All the sequence alignment and homology comparison
were done with MacVector 7.0.
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